Basic & Clinical Pharmacology & Toxicology最新文献

{"title":"COMMITTEES","authors":"","doi":"10.1111/bcpt.14061","DOIUrl":"10.1111/bcpt.14061","url":null,"abstract":"","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 S1","pages":"3-4"},"PeriodicalIF":2.7,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14061","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Communications","authors":"","doi":"10.1111/bcpt.14063","DOIUrl":"10.1111/bcpt.14063","url":null,"abstract":"<p><b>#44</b></p><p><b>Late adverse events in patients treated with CAR T-cell for aggressive B-cell non-Hodgkin Lymphoma: A prospective, multicentre, real-world study</b></p><p>L. Camacho-Arteaga<sup>1,2</sup>, G. Iacoboni<sup>1,3</sup>, M. Kwon<sup>4,5,6</sup>, R. Hernani<sup>7,8</sup>, L. López-Corral<sup>9,10</sup>, L. M. Leguízamo-Martínez<sup>11,12,13</sup>, M. Guerreiro<sup>14</sup>, C. Alonso-Martínez<sup>1</sup>, P. Barba<sup>1,3,2</sup> and A. Agustí<sup>1,2</sup></p><p><sup>1</sup><i>Hospital Universitari Vall d'Hebron, Barcelona, Spain;</i> <sup>2</sup><i>Universitat Autònoma de Barcelona, Barcelona, Spain;</i> <sup>3</sup><i>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain;</i> <sup>4</sup><i>Hospital General Universitario Gregorio Marañón, Madrid, Spain;</i> <sup>5</sup><i>Institute of Health Resarch Gregorio Marañón, Madrid, Spain;</i> <sup>6</sup><i>Universidad Complutense de Madrid, Madrid, Spain;</i> <sup>7</sup><i>Hospital Clínico Universitario, Valencia, Spain;</i> <sup>8</sup><i>INCLIVA Research Institute, Valencia, Spain;</i> <sup>9</sup><i>Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain;</i> <sup>10</sup><i>Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain;</i> <sup>11</sup><i>Hospital Clinic of Barcelona, Barcelona, Spain;</i> <sup>12</sup><i>Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;</i> <sup>13</sup><i>Universitat de Barcelona, Barcelona, Spain;</i> <sup>14</sup><i>Hospital Universitari i Politecnic La Fe, Valencia, Spain</i></p><p><b>Objective</b>: Acute adverse events after CAR T-cell infusion are well known, but less information is available about long-term toxicities and their incidence. Our research aimed to describe the occurrence of any late adverse event (AE) in patients with an aggressive B-cell non-Hodgkin lymphoma (NHL) treated with CD19 CAR-T cells.</p><p><b>Material and/or methods</b>: A prospective, observational study was carried out in six Spanish centres from 1 September 2018 to 31 December 2022. All adult patients diagnosed with an aggressive B-cell NHL treated with a commercial CAR T-cell product (tisagenlecleucel or axicabtagene ciloleucel) who had not received any other treatment for their disease at 3 months post-infusion were included. Late AEs were defined as those that either persisted or occurred beyond 3 months post-infusion. Incidence and severity of late AE episodes were analysed.</p><p><b>Results</b>: A total of 172 infused patients were evaluated with a median follow-up of 13.9 months (IQR8.2–23.8). One hundred thirty-five (78.5%) patients experienced at least one late AE of any grade, being infection episodes with an incidence of 5.63 per 100 person-months, [CI 95% 4.50–7.04], the most frequent, followed by neutropenia (3.59 per 100 person-months [CI 95% 2.89–4.53]) and thrombocytopenia (2.24 per 100 person-months [CI 95% 1.65–3.02]). There were no differences in the late AEs incidence betwee","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 S1","pages":"15-24"},"PeriodicalIF":2.7,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An overview of major depression disorder: The endocannabinoid system as a potential target for therapy.","authors":"Sergio Zarazúa-Guzmán, Jorge Genaro Vicente-Martínez, Juan Manuel Pinos-Rodríguez, Jaime Iván Arevalo-Villalobos","doi":"10.1111/bcpt.14089","DOIUrl":"https://doi.org/10.1111/bcpt.14089","url":null,"abstract":"<p><p>Major depressive disorder is the psychiatric disease with the highest global prevalence, impacting social functioning and decreasing the quality of life. The partial pathophysiological knowledge of the disease, the economic burden and the low remission rates are sufficient justification to carry out an update on the subject in the search for new therapeutic approaches and targets. The endocannabinoid system has been linked to the development of depression, and its stimulation or antagonism is a promising approach in the treatment of major depressive disorder. Cannabidiol (CBD) and its properties have been widely studied recently; its analgesic, anti-inflammatory, antineoplastic and neuroprotective roles have even been reported in animal models and clinical trials, achieving its approved use for certain neurodegenerative pathologies. The use of CBD in depression biomodels and clinical trials has not been the exception, and here we contrast the current evidence of its administration and pharmacology against the pathological mechanisms of major depressive disorder.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytotoxicity, genotoxicity and mutagenicity of mixed ternary mononuclear Mg complex based on valproic acid with 1,10-phenanthroline in Saccharomyces cerevisiae and V79 cells.","authors":"Julia Vanini, Gabriel Berbigier Rodrigues, André Luiz Mendes Juchem, Temenouga Nikolova Guecheva, Sidnei Moura, Françoise Dumas, João Antonio Pêgas Henriques, Iuri Marques de Oliveira","doi":"10.1111/bcpt.14091","DOIUrl":"https://doi.org/10.1111/bcpt.14091","url":null,"abstract":"<p><p>Valproic acid (VA) is a widely used drug for the treatment of diseases affecting the central nervous system. Due to its epigenetic modulatory potential, it has been studied for possible therapeutic application in anticancer therapies. However, the VA exhibits different side effects in its application. Thus, synthetic coordination complexes with valproate can generate promising candidates for new active drugs with reduced toxicity. In this sense, we investigated the genotoxic and mutagenic potential of the sodium valproate and of the mixed ternary mononuclear Mg complex based on VA with 1,10-phenanthroline (Phen) ligand - [Mg (Valp)₂Phen], in Saccharomyces cerevisiae and V79 cells. The MTT and clonal survival assays in V79 cells indicated that the Mg complex has higher cytotoxicity than sodium valproate. A similar cytotoxicity profile is observed in yeast. This fact is possibly due to the intercalation capacity of [Mg(Valp)₂Phen], inducing DNA strand breaks, as observed in the comet assay and micronucleus test. In this sense, members of the NER, HR, NHEJ and TLS repair pathways are required for the repair of DNA lesions induced by [Mg(Valp)₂Phen]. Interestingly, BER proteins apparently increase the cytotoxic potential of the drug. Furthermore, the [Mg(Valp)₂Phen] showed higher cytotoxicity in V79 cells and yeast when compared to sodium valproate indicating applicability as a cytotoxic agent.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: Epigallocatechin-3-gallate(−) protects Chang liver cells against ethanol-induced cytotoxicity and apoptosis","authors":"","doi":"10.1111/bcpt.14086","DOIUrl":"10.1111/bcpt.14086","url":null,"abstract":"<p><b>RETRACTION</b>: S. Kaviarasan, N. Ramamurthy, P. Gunasekaran, E. Varalakshmi and C. V. Anuradha, “Epigallocatechin-3-gallate(-) Protects Chang Liver Cells against Ethanol-induced Cytotoxicity and Apoptosis,” <i>Basic &amp; Clinical Pharmacology &amp; Toxicology</i> 100, No. 3 (2007): 151–156, https://doi.org/10.1111/j.1742-7843.2006.00036.x.</p><p>The above article, published online on 16 January 2007 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editors-in-Chief, Jens Lykkesfeldt and Ulf Simonsen; the Nordic Association for the Publication of BCPT (formerly the Nordic Pharmacological Society); and John Wiley &amp; Sons Ltd. The retraction has been agreed due to concerns that the images presented in Figure 2a–c are duplicates of images published earlier by the same author group in another journal. Although two of the duplicate images appear to represent the same experiment, the image presented in Figure 2c of this article represents a different treatment to that of the duplicate image in the earlier article. Furthermore, several of the control and EtOH values presented in Table 1 and the flow cytometry panels presented in Figure 3a,b are identical to those shown in the earlier article. As a result, the editors consider the results and conclusions of this article to be invalid. The authors were informed of the decision to retract; however, all but one were unavailable for comment. Elango Varalakshmi stated that she did not consent to be listed as an author for this publication.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 5","pages":"664"},"PeriodicalIF":2.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dementia and neurodegenerative diseases: What is known and what is promising at the cellular and molecular level","authors":"Olesia F. Moroz,&nbsp;Viktoriia I. Kravchenko,&nbsp;Bohdan O. Kushch,&nbsp;Alexander V. Zholos","doi":"10.1111/bcpt.14087","DOIUrl":"10.1111/bcpt.14087","url":null,"abstract":"<p>Millions of people worldwide are affected by neurodegenerative diseases and cognitive impairment, which includes dementia, while there are only symptomatic treatments available for this syndrome at present. However, several important prospective drug targets have been identified in recent years that can potentially arrest or even reverse the progression of neurodegenerative diseases. Their natural or synthetic ligands are currently in the experimental stage of drug development. In vitro and preclinical (e.g. using animal models) studies confirm their therapeutic potential, but clinical trials often fail or produce conflicting results. Here, we first review the complexity and typology of dementia, followed by the discussion of currently available treatments, and, finally, some novel molecular and cellular approaches to this problem.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 5","pages":"550-560"},"PeriodicalIF":2.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isovaleramide attenuates ethylene glycol poisoning-induced acute kidney injury and reduces mortality by inhibiting alcohol dehydrogenase activity in rats","authors":"Kai Yang,&nbsp;Xiaoxia Zhang,&nbsp;Jianzhong Yang,&nbsp;Xiaokelaiti Huojiahemaiti,&nbsp;Xinpeng Li,&nbsp;Ziyang Liu,&nbsp;Peng Peng","doi":"10.1111/bcpt.14084","DOIUrl":"10.1111/bcpt.14084","url":null,"abstract":"<p>We explored the potential value of the alcohol dehydrogenase (ADH) inhibitor isovaleramide (ISO) in the treatment of acute ethylene glycol (EG) poisoning-induced acute kidney injury. Sprague–Dawley rats were divided into the control, EG, EG + ISO (10 mg/kg) and EG + ISO (20 mg/kg) groups. It is found that ISO intervention significantly reduced the ADH activity in liver tissue by using visible spectrophotometry, inhibited the in vivo metabolism of EG by using gas chromatography, lowered the levels of toxic metabolites glycolic acid and oxalic acid by using high-performance liquid chromatography and decreased the expression of kidney injury markers serum creatinine (sCr), KIM-1, neutrophil gelatinase-associated lipocalin (NGAL) and liver fatty acid-binding protein (L-FABP) by ELISA. Additionally, Western blotting results showed that ISO down-regulated the expression of apoptotic factors Bax and cleaved caspase-3 in the kidneys and upregulated the expression of antiapoptotic factor Bcl-2. Pizzolato staining and polarized light microscopy results revealed the reduced deposition of calcium oxalate crystals in the kidney tubules. Using haematoxylin and eosin (H&amp;E), periodic acid-Schiff (PAS) and Masson staining, we found attenuated kidney tissue pathological injury. Finally, ISO significantly reduced the mortality rate. In conclusion, ISO has the potential to be a valuable drug for the treatment of EG poisoning-induced acute kidney injury.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 5","pages":"641-654"},"PeriodicalIF":2.7,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diallyl trisulfide alleviates dextran sulphate sodium-induced colitis in mice by inhibiting NLRP3 inflammasome activation via ROS/Trx-1 pathway","authors":"Yue He,&nbsp;Ling Xiao,&nbsp;Jing Zhang,&nbsp;Yanrong Zhu,&nbsp;Yilei Guo,&nbsp;Yufeng Xia,&nbsp;Huatou Zhao,&nbsp;Zhifeng Wei,&nbsp;Yue Dai","doi":"10.1111/bcpt.14083","DOIUrl":"10.1111/bcpt.14083","url":null,"abstract":"<p>Diallyl trisulfide (DATS), a sulphur-containing compound isolated from the medicinal food plant garlic, has been previously reported to attenuate experimental colitis induced by either dextran sodium sulphate (DSS) or 2,4,6-trinitrobenzenesulfonic acid (TNBS) in mice; however, the underlying mechanism remains to be identified. In this study, we deciphered the key mechanism by which DATS alleviates ulcerative colitis (UC). We showed that oral administration of DATS for 10 consecutive days greatly restrained the infiltration of macrophages and the pathological changes in colonic tissues of mice with DSS-induced colitis. DATS treatment notably dampened the content of IL-1β and IL-18 and suppressed NLRP3 inflammasome activation in colon. Mechanistically, DATS effectively diminished the generation of ROS in macrophages. The suppressive effect of DATS on the activation of NLRP3 inflammasome and downregulation of IL-18 and IL-1β levels was blunted by xanthine oxidase. Further studies revealed that DATS inhibited NF-κB pathway activation by suppressing the expression of Trx-1, thereby inhibiting NLRP3 inflammasome activation. Trx-1 overexpression and interference in macrophages promoted and diminished NLRP3 inflammasome activation, respectively. In summary, garlic and its main active ingredient DATS have potentials to prevent and treat UC, and DATS functions by inhibiting NLRP3 inflammasome activation via Trx-1/ROS pathway.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 5","pages":"593-606"},"PeriodicalIF":2.7,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage and chondrocyte phenotypes in inflammation","authors":"Antti Pemmari,&nbsp;Eeva Moilanen","doi":"10.1111/bcpt.14085","DOIUrl":"10.1111/bcpt.14085","url":null,"abstract":"<p>Inflammation is a complex biological process protecting the body from diverse external threats. Effectively performing this task requires an intricate, well-regulated interplay of different cells and tissues. Furthermore, several cells participating in inflammation can assume diverse phenotypes.</p><p>A classic and relatively well-studied example of phenotypic diversity in inflammation is macrophage polarization. Based on the T_H1/T_H2 phenotypes of T helper cells, this scheme has proinflammatory “classical/M1” activation contrasted with the anti-inflammatory and healing-promoting “alternative/M2” phenotype. Some authors have extended the concept into an M17 phenotype induced by the classic T_H17 cytokine IL-17. Phenotypic changes in chondrocytes have also been studied especially in the context of osteoarthritis (OA), and there are indications that these cells can also assume polarized phenotypes at least partly analogous to those of T_H cells and macrophages. The therapeutic success of biological agents targeting T_H1/T_H2/T_H17 inductor and/or effector cytokines displays the utility of the concept of polarization. The aim of this focused review is to survey the internal and external factors affecting macrophage and chondrocyte phenotypes (such as inflammatory cytokines, widely used medications and natural products) and to explore the possibility of ameliorating pathological states by modulating these phenotypes.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 5","pages":"537-549"},"PeriodicalIF":2.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of hypothermia and hypoxia on cytochrome P450-mediated drug metabolism in neonatal Göttingen minipigs","authors":"Marina-Stefania Stroe,&nbsp;Laura De Clerck,&nbsp;Maarten Dhaenens,&nbsp;Rachel Siân Dennis,&nbsp;Dieter Deforce,&nbsp;Sebastien Carpentier,&nbsp;Pieter Annaert,&nbsp;Karen Leys,&nbsp;Anne Smits,&nbsp;Karel Allegaert,&nbsp;Chris Van Ginneken,&nbsp;Steven Van Cruchten","doi":"10.1111/bcpt.14081","DOIUrl":"10.1111/bcpt.14081","url":null,"abstract":"<p>Asphyxiated neonates often undergo therapeutic hypothermia (TH) to reduce morbidity and mortality. As perinatal asphyxia and TH impact neonatal physiology, this could also influence enzyme functionality. Therefore, this study aimed to unravel the impact of age, hypothermia and hypoxia on porcine hepatic cytochrome P450 (CYP) gene expression, protein abundance and activity. Hepatic CYP expression, protein abundance and activity were assessed in naive adult and neonatal Göttingen minipigs, alongside those from an (non-survival) in vivo study, where four conditions—control (C), therapeutic hypothermia (TH), hypoxia (H), hypoxia and TH (H + TH)—were examined. Naive neonatal Göttingen minipigs exhibited 75% lower general CYP activity and different gene expression patterns than adults. In vitro hypothermia (33°C) decreased general CYP activity in adult liver microsomes by 36%. Gene expression was not different between TH and C while hypoxia up-regulated several genes (i.e., <i>CYP3A29</i> [expression ratio; <i>E</i>_<i>R</i> = 5.1472] and CYP2C33 [<i>E</i>_<i>R</i> = 3.2292] in the H group and CYP2C33 [<i>E</i>_<i>R</i> = 2.4914] and CYP2C42 [<i>E</i>_<i>R</i> = 4.0197] in the H + TH group). The medical treatment and the interventions over 24 h, along with hypoxia and TH, affected the protein abundance. These data on CYP expression, abundance and activity in young animals can be valuable in building physiologically-based pharmacokinetic models for neonatal drug dose predictions.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 5","pages":"620-640"},"PeriodicalIF":2.7,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14081","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}